Tevogen Bio Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TVGN research report →
Price Chart
About the company
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID.
- CEO
- Ryan H. Saadi
- IPO
- 2022
- Employees
- 18
- HQ
- Warren, NJ, US
Get TickerSpark's AI analysis on TVGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $27.03M
- P/E
- -1.11
- Fwd P/E
- 0.42
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -2.80
- EV/EBITDA
- -1.38
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 248.50%
- ROIC
- -3850.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-26,140,515
- Net Income
- $-26,275,432-159.8%
- EPS
- $-8.08-72.6%
- OCF Growth
- -2.7%
- FCF Growth
- -3.3%
- 52W High
- $39.00
- 52W Low
- $3.64
- 50D MA
- $6.93
- 200D MA
- $9.28
- Beta
- 0.20
- RSI (14)
- 39
- Avg Volume
- 10.10K
No earnings-call transcripts are available for TVGN yet.
- Free Float
- 25.5%
- Shares Outstanding
- 4.16M
- Float Shares
- 1.06M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.13M | ▲ 44.71K |
| Vanguard Capital Management LLC | 23.98K | ▼ 9.27K |
| Morgan Stanley | 18.81K | ▲ 1.48K |
| Aqr Capital Management LLC | 17.24K | ▲ 17.24K |
| Goldman Sachs Group Inc | 14.16K | ▲ 14.16K |
| Jane Street Group, LLC | 11.18K | ▲ 11.18K |
| Fmr LLC | 9.83K | ▼ 331 |
| Russell Investments Group, Ltd. | 6.53K | ▲ 726 |
| Tower Research Capital LLC (Trc) | 1.49K | ▲ 553 |
| Ubs Group AG | 1.08K | ▼ 2.48K |
| Vanguard Fiduciary Trust Co | 838 | ▼ 530 |
| Gamma Investing LLC | 762 | ▲ 622 |
Held by 26 ETFs
Biggest fund positions in TVGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 14, 26 | Saadi Ryan H. | other | 8,000,000 |
| Sep 14, 26 | Desai Kirti | other | 750,000 |
| Sep 11, 26 | Goh Keow Lin | other | 75,000 |
| Sep 11, 26 | PODLOGAR SUSAN M | other | 75,000 |
| Sep 11, 26 | Sordillo Victor J. | other | 75,000 |
| Sep 11, 26 | Feike Jeffrey L. | other | 75,000 |
| Sep 11, 26 | Patton Curtis L. | other | 75,000 |
| Jul 10, 26 | Sordillo Victor J. | other | 40,000 |
| Jul 10, 26 | Saadi Ryan H. | other | 1,220,000 |
| Jul 10, 26 | PODLOGAR SUSAN M | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TVGN coverage
Recent articles, reports, and earnings notes.
No research on TVGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TVGN report →Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
globenewswire.com · Sep 30
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
globenewswire.com · Jul 29
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
globenewswire.com · Jul 13
Tevogen Announces Formation of a Healthcare Services Initiative
globenewswire.com · Jun 9
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
globenewswire.com · May 28
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
globenewswire.com · May 21
Letter to Shareholders from CEO Dr. Ryan Saadi
globenewswire.com · May 18
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
globenewswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.